Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Pediatric Sarcoma
NCT ID: NCT00592592 (View complete trial on
DFCI Protocol ID: 04-188


The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.


Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital, Children's Hospital Boston, Brigham and Women's Hospital

Overall PI:
Torunn Yock, MD, Massachusetts General Hospital

Site-responsible Investigators:
Karen Marcus, MD, Brigham and Women's Hospital

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria: - Patients with biopsy proven newly diagnosed rhabdomyosarcoma. - Patients less than or equal to 21 years of age. - Patients must be treated with a standardly accepted chemotherapy regimen. - May not have metastatic disease unless aged 2-10 with embryonal histology. - Must be willing to receive follow-up care for a minimum of five years after treatment at MGH and annual visits unless it is too difficult to return to MGH for follow-up care. In that event, they must be willing to have their outside medical information released to us to track the results. - Timing of radiation must be according to the IRB protocol upon which the patient is treated within either 35 days of last chemotherapy or surgery. Exclusion Criteria: - Life expectancy of less than 2 years. - Co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury or collagen vascular disease. - Patients who are pregnant - Previous treatment with radiation therapy.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online